11,291 reports of this reaction
2.1% of all METFORMIN ER 750 MG reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for METFORMIN ER 750 MG, manufactured by Granules Pharmaceuticals Inc.. There are 11,291 FDA adverse event reports linking METFORMIN ER 750 MG to DYSPNOEA. This represents approximately 2.1% of all 532,492 adverse event reports for this drug.
Patients taking METFORMIN ER 750 MG who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for METFORMIN ER 750 MG, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for METFORMIN ER 750 MG:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 11,291 FDA reports for METFORMIN ER 750 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.1% of all adverse event reports for METFORMIN ER 750 MG, making it a notable side effect.
If you experience dyspnoea while taking METFORMIN ER 750 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.